$26.38
+0.07
(+0.27%)▲
0.71%
Downside
Day's Volatility :0.85%
Upside
0.13%
28.34%
Downside
52 Weeks Volatility :42.56%
Upside
19.84%
Period | Koninklijke Philips N.v | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -11.65% | -6.9% | 0.0% |
6 Months | -2.94% | -1.7% | 0.0% |
1 Year | 24.55% | 10.4% | 0.0% |
3 Years | -29.38% | 8.8% | -24.1% |
Market Capitalization | 24.2B |
Book Value | $12.72 |
Earnings Per Share (EPS) | -0.51 |
PEG Ratio | 0.36 |
Wall Street Target Price | 34.5 |
Profit Margin | -1.82% |
Operating Margin TTM | 7.72% |
Return On Assets TTM | 1.36% |
Return On Equity TTM | -4.59% |
Revenue TTM | 18.0B |
Revenue Per Share TTM | 19.75 |
Quarterly Revenue Growth YOY | -2.1% |
Gross Profit TTM | 7.2B |
EBITDA | 1.6B |
Diluted Eps TTM | -0.51 |
Quarterly Earnings Growth YOY | 1.07 |
EPS Estimate Current Year | 1.35 |
EPS Estimate Next Year | 1.81 |
EPS Estimate Current Quarter | 0.37 |
EPS Estimate Next Quarter | 0.55 |
What analysts predicted
Upside of 30.78%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 20.6B | ↑ 1.92% |
Net Income | 1.2B | ↓ 34.22% |
Net Profit Margin | 6.02% | ↓ 3.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 21.6B | ↑ 7.51% |
Net Income | 1.3B | ↑ 7.16% |
Net Profit Margin | 6.0% | ↓ 0.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 23.8B | ↑ 0.27% |
Net Income | 1.4B | ↑ 1.63% |
Net Profit Margin | 6.08% | ↑ 0.08% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 19.4B | ↓ 12.18% |
Net Income | 691.8M | ↓ 48.44% |
Net Profit Margin | 3.57% | ↓ 2.51% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 18.9B | ↑ 3.91% |
Net Income | -1.7B | ↓ 364.38% |
Net Profit Margin | -9.08% | ↓ 12.65% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 19.8B | ↑ 1.92% |
Net Income | -508.4M | ↓ 71.2% |
Net Profit Margin | -2.56% | ↑ 6.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 7.27% |
Net Income | 78.1M | ↓ 110.86% |
Net Profit Margin | 1.61% | ↑ 17.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 0.02% |
Net Income | 93.9M | ↑ 22.22% |
Net Profit Margin | 1.97% | ↑ 0.36% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.5B | ↑ 13.22% |
Net Income | 42.5M | ↓ 55.68% |
Net Profit Margin | 0.77% | ↓ 1.2% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.5B | ↓ 18.25% |
Net Income | -1.1B | ↓ 2661.54% |
Net Profit Margin | -24.14% | ↓ 24.91% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 7.83% |
Net Income | 485.3M | ↓ 145.15% |
Net Profit Margin | 10.11% | ↑ 34.25% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.4B | ↓ 1.9% |
Net Income | 181.0M | ↓ 59.87% |
Net Profit Margin | 4.14% | ↓ 5.97% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 29.6B | ↑ 2.78% |
Total Liabilities | 15.8B | ↑ 4.59% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.0B | ↑ 3.7% |
Total Liabilities | 16.0B | ↑ 3.28% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 33.7B | ↑ 2.71% |
Total Liabilities | 19.2B | ↑ 10.13% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 35.0B | ↑ 11.72% |
Total Liabilities | 18.6B | ↑ 4.27% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 32.5B | ↓ 0.88% |
Total Liabilities | 18.4B | ↑ 5.57% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 32.1B | ↓ 4.18% |
Total Liabilities | 18.9B | ↓ 0.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.0B | ↓ 3.85% |
Total Liabilities | 18.8B | ↑ 6.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.1B | ↓ 0.34% |
Total Liabilities | 18.9B | - |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 31.7B | - |
Total Liabilities | 18.9B | - |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↓ 4.81% |
Investing Cash Flow | -1.7B | ↓ 53.55% |
Financing Cash Flow | -1.4B | ↓ 2267.27% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.3B | ↑ 14.1% |
Investing Cash Flow | -670.1M | ↓ 59.42% |
Financing Cash Flow | -1.9B | ↑ 39.68% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.4B | ↑ 36.73% |
Investing Cash Flow | -1.6B | ↑ 118.24% |
Financing Cash Flow | 587.5M | ↓ 129.01% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 41.34% |
Investing Cash Flow | -4.2B | ↑ 179.03% |
Financing Cash Flow | -2.7B | ↓ 585.92% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -183.1M | ↓ 110.62% |
Investing Cash Flow | -1.6B | ↓ 59.5% |
Financing Cash Flow | 529.1M | ↓ 121.3% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -625.2M | ↓ 111.74% |
Investing Cash Flow | -927.7M | ↓ 76.12% |
Financing Cash Flow | 369.2M | ↓ 114.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 110.1M | ↓ 117.6% |
Investing Cash Flow | -1.6B | ↑ 69.56% |
Financing Cash Flow | 529.1M | ↑ 43.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 390.5M | ↑ 246.15% |
Investing Cash Flow | -389.4M | ↓ 75.86% |
Financing Cash Flow | -182.2M | ↓ 133.6% |
Sell
Neutral
Buy
Koninklijke Philips N.v is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Koninklijke Philips N.v | -17.79% | -2.94% | 24.55% | -29.38% | -38.44% |
Stryker Corporation | 6.59% | 16.31% | 32.68% | 49.88% | 93.53% |
Boston Scientific Corp. | 3.97% | 21.4% | 65.07% | 124.82% | 118.64% |
Edwards Lifesciences Corp. | 1.65% | -21.98% | 4.95% | -38.71% | -12.32% |
Abbott Laboratories | 0.98% | 11.87% | 14.18% | -6.39% | 40.03% |
Medtronic Plc | -7.0% | -1.19% | 8.13% | -27.5% | -23.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Koninklijke Philips N.v | 75.3 | NA | 0.36 | 1.35 | -0.05 | 0.01 | NA | 12.72 |
Stryker Corporation | 41.34 | 41.34 | 2.69 | 12.05 | 0.19 | 0.07 | 0.01 | 52.86 |
Boston Scientific Corp. | 74.52 | 74.52 | 1.64 | 2.46 | 0.09 | 0.05 | NA | 14.05 |
Edwards Lifesciences Corp. | 27.17 | 27.17 | 6.38 | 2.53 | 0.19 | 0.11 | NA | 16.18 |
Abbott Laboratories | 35.56 | 35.56 | 2.25 | 4.68 | 0.15 | 0.06 | 0.02 | 22.94 |
Medtronic Plc | 29.55 | 29.55 | 1.63 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Koninklijke Philips N.v | Hold | $24.2B | -38.44% | 75.3 | -1.82% |
Stryker Corporation | Buy | $147.0B | 93.53% | 41.34 | 16.34% |
Boston Scientific Corp. | Buy | $132.9B | 118.64% | 74.52 | 11.26% |
Edwards Lifesciences Corp. | Buy | $41.5B | -12.32% | 27.17 | 65.86% |
Abbott Laboratories | Buy | $203.2B | 40.03% | 35.56 | 13.99% |
Medtronic Plc | Buy | $110.3B | -23.53% | 29.55 | 12.06% |
Insights on Koninklijke Philips N.v
Revenue is down for the last 2 quarters, 4.46B → 4.37B (in $), with an average decrease of 1.9% per quarter
Netprofit is down for the last 2 quarters, 451.0M → 181.0M (in $), with an average decrease of 59.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 40.5%
In the last 3 years, Boston Scientific Corp. has given 124.8% return, outperforming this stock by 154.2%
Mondrian Investment Partners Ltd
Fiduciary Management, Inc. of Milwaukee
FMR Inc
Morgan Stanley - Brokerage Accounts
BlackRock Inc
Dimensional Fund Advisors, Inc.
In the quarter ending September,2022. Koninklijke Philips N.v has declared dividend of $0.91
Read MoreKoninklijke Philips N.V., commonly shortened to Philips, is a Dutch multinational conglomerate corporation that was founded in Eindhoven in 1891. Since 1997, it has been mostly headquartered in Amsterdam, though the Benelux headquarters is still in Eindhoven.
Organization | Koninklijke Philips N.v |
Employees | 69282 |
CEO | Mr. Roy Jakobs |
Industry | Electronic Technology |
Nisource Inc.
$26.38
+0.27%
Russell 2000 Ishares Etf
$26.38
+0.27%
Mid-america Apartment Communities Inc.
$26.38
+0.27%
S&p 500 Growth Index Ishares
$26.38
+0.27%
Lyondellbasell Industries N.v.
$26.38
+0.27%
Targa Resources Corp.
$26.38
+0.27%
Thomson Reuters Corp.
$26.38
+0.27%
Zimmer Biomet Holdings, Inc.
$26.38
+0.27%
Logitech International Sa
$26.38
+0.27%